Vascular-targeting agent

From Food & Medicine Encyclopedia

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.<ref>, 

 Vascular Targeting Agents as Cancer Therapeutics, 
 , 
 2004,
 
 
 
 
 
 
 Full text,</ref>

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

Clinical trials[edit]

Phase II : ZD6126, CA4P, plinabulin (NPI-2358)<ref>

NPI-2358(link). {{{website}}}. clinicaltrials.gov.



</ref><ref>Monica M. Mita, 

 Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas, 
 Clin Cancer Res, 
 2010,
 Vol. 16(Issue: 23),
 pp. 5892–5899,
 DOI: 10.1158/1078-0432.CCR-10-1096,
 PMID: 21138873,</ref><ref name=Staff2009>Staff, 
 Clinical Trials Update, 
 Genetic Engineering & Biotechnology News, 
 2009,
 Vol. 29(Issue: 8),
 pp. 58,</ref>

Phase III : DMXAA (ASA404).

References[edit]

Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.

This article is a stub.

You can help WikiMD by registering to expand it.
Editing is available only to registered and verified users.
WikiMD is a comprehensive, free health & wellness encyclopedia.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Vascular-targeting_agent&oldid=6527011"